Journey Medical (DERM)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	22.46 mm	22.46 mm	22.46 mm	22.46 mm	22.46 mm	22.46 mm
Cash burn (monthly)	483.67 k	190.67 k	964.67 k	1.57 mm	385.67 k	2.32 mm
Cash used (since last report)	2.57 mm	1.01 mm	5.13 mm	8.32 mm	2.05 mm	12.34 mm
Cash remaining	19.89 mm	21.45 mm	17.34 mm	14.14 mm	20.41 mm	10.12 mm
Runway (months of cash)	41.1	112.5	18.0	9.0	52.9	4.4

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

DERM institutional ownership history Ownership history

66.0% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	38	38	–
Opened positions	7	8	-12.5%
Closed positions	7	6	+16.7%
Increased positions	11	8	+37.5%
Reduced positions	9	10	-10.0%

13F shares	Current	Prev Q	Change
Total value	13.52 bn	9.30 bn	+45.3%
Total shares	13.79 mm	12.18 mm	+13.2%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
FBIO Fortress Biotech	10.01 mm	$82.09 mm	0.0%
Tang Capital Management	1.73 mm	$6.75 bn	NEW
Cambridge Investment Research Advisors	328.11 k	$1.28 mm	+4.3%
Vanguard	325.17 k	$1.27 bn	0.0%
Renaissance Technologies	236.00 k	$922.76 mm	-12.0%
AFG American Financial	180.00 k	$703.80 mm	0.0%
PVG Asset Management	168.11 k	$657.29 mm	+0.3%
Geode Capital Management	109.22 k	$427.14 mm	+0.7%
Envestnet Asset Management	103.56 k	$404.91 mm	-5.5%
Geneos Wealth Management	63.28 k	$247.43 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
Tang Capital Management	1.73 mm	+1.73 mm	NEW
Rosalind Advisors	0.00	-105.92 k	EXIT
Citadel Advisors	44.57 k	+44.57 k	NEW
Neuberger Berman	28.50 k	-35.90 k	-55.7%
Renaissance Technologies	236.00 k	-32.20 k	-12.0%
Acadian Asset Management	17.36 k	-24.35 k	-58.4%
Walleye Capital	0.00	-23.10 k	EXIT
UBS UBS	22.36 k	+22.36 k	NEW
Perkins Capital Management	0.00	-22.00 k	EXIT
Dimensional Fund Advisors	20.45 k	+20.45 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

DERM insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
5 Mar 25	Claude Maraoui	Common Stock, $0.0001 par value	Sell	Dispose S	No	No	5.13	18,147	93.09 k	2,092,874
4 Mar 25	Claude Maraoui	Common Stock, $0.0001 par value	Sell	Dispose S	No	No	5.04	28,901	145.66 k	2,111,021
3 Mar 25	Claude Maraoui	Common Stock, $0.0001 par value	Sell	Dispose S	No	No	5.19	23,508	122.01 k	2,139,922
21 Feb 25	Joseph Benesch	Common Stock, $0.0001 par value	Sell	Dispose S	No	No	5.19	1,365	7.08 k	45,966
1 Aug 24	Joseph Benesch	Common Stock, $0.0001 par value	Sell	Dispose S	No	No	5.47	9,324	51.00 k	47,331
23 Jul 24	Joseph Benesch	Common Stock, $0.0001 par value	Sell	Dispose S	No	No	5.4	4,055	21.90 k	56,655
19 Jul 24	Michael Cooper Pearce	Common Stock, $0.0001 par value	Grant	Acquire A	No	No	0	30,000	0.00	30,000

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Journey Medical Announces Publication In The Journal Of The American Medical Association - Dermatology Of The Phase 3 Clinical Trial Results Of Emrosi To Treat Rosacea; DFD-29 Achieved The Co-Primary And All Secondary Endpoints With No Significant Safety Issues When Administered Once Daily For 16 Weeks

5 Mar 25

DFD-29 (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) achieved the co-primary and all secondary endpoints with no significant safety issues when

Press releases

From Benzinga Pro

Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea

5 Mar 25

Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida

4 Mar 25

SCOTTSDALE, Ariz., March 04, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food

Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

23 Jan 25

SCOTTSDALE, Ariz., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food